Overview
Mazdutide (IBI362) is described as “a long‑acting dual GLP‑1/glucagon receptor agonist developed for chronic weight management and type 2 diabetes.” Clinical research demonstrates substantial weight reduction ranging from 6–14% over 24–48 weeks with predominantly mild gastrointestinal side effects.
Key Specifications
Reconstitution Standard:
– Add 3.0 mL bacteriostatic water to achieve approximately 1.67 mg/mL concentration
– At this dilution, 1 unit on a U-100 insulin syringe equals roughly 16.7 micrograms
Storage Requirements:
– Lyophilized form: freeze at −20 °C (−4 °F)
– After reconstitution: refrigerate at 2–8 °C (35.6–46.4 °F)
– Avoid freeze-thaw cycles to prevent peptide denaturation
– Discard reconstituted vials after 28 days
Standard Dosing Protocol (Gradual Titration)
| Period | Weekly Dose | Syringe Units | Volume |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg | 150 units | 1.50 mL |
| Weeks 5–8+ | 5 mg | 300 units | 3.00 mL |
Administration: Once-weekly subcutaneous injection with gradual dose increases to improve tolerability.
Advanced Protocol (Higher Concentration)
For doses potentially reaching 10 mg weekly, a 2.0 mL reconstitution (2.5 mg/mL) is detailed. Doses exceeding 3.0 mL total volume should be split into two separate injections at different anatomical sites.
Mechanism of Action
The medication functions as a dual agonist targeting both GLP-1 and glucagon receptors, combining “appetite‑suppressing and glucose‑lowering effects of GLP‑1 with the energy‑expenditure benefits of glucagon activation.” Phase 2 studies showed weight reductions of 6.7–11.3% over 24 weeks at 3–6 mg weekly doses. A 48-week phase 3 trial demonstrated sustained losses of 11–14% with 4–6 mg maintenance.
Clinical Benefits
– Significant body weight reduction documented in obesity trials
– Type 2 diabetes populations achieved approximately 1.7% HbA1c reduction alongside 7% weight loss
– Improved lipid profiles and glucose control
– Once-weekly dosing enhances medication adherence
Potential Side Effects
Common adverse events:
– Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are most frequent but typically mild-to-moderate
– Injection-site reactions including redness and swelling
– Gradual titration significantly reduces discontinuation rates related to tolerability
Injection Administration
– Cleanse vial stopper and injection site with alcohol swabs; allow air-drying
– Insert needle at 45–90° angle into subcutaneous fatty tissue
– Do not aspirate for subcutaneous administration
– Inject over 5–10 seconds
– Rotate sites systematically: abdomen (2+ inches from navel), thighs, or upper arms
– Use new sterile syringe for each injection
Protocol Duration
– Minimum 8 weeks recommended
– Clinical evidence supports 12–48 week protocols
– Administer on the same day each week
– Rotate injection sites to minimize local irritation
Supplies Required (Example: 8-Week Protocol)
– Peptide vials: approximately 6 units
– U-100 insulin syringes: 8 syringes
– Bacteriostatic water: 18 mL (two 10 mL bottles)
– Alcohol swabs: 16 minimum (one 100-count box recommended)
Lifestyle Considerations
– Maintain balanced, nutrient-dense diet with adequate protein
– Combine resistance and aerobic exercise
– Prioritize 7–9 hours nightly sleep
– Monitor hydration and electrolyte intake, especially during initial titration
Important Disclaimer
This educational protocol is for research purposes only and does not constitute medical advice, diagnosis, or treatment. Mazdutide remains an investigational peptide not approved for prescription use in most countries as of 2025 (initial approval granted in China for obesity treatment). Consultation with qualified healthcare professionals is essential before considering any peptide protocol.